Status:
UNKNOWN
Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy
Lead Sponsor:
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Collaborating Sponsors:
Affiliated Hospital of Nanjing University of Chinese Medicine
The Second Affiliated Hospital of Dalian Medical University
Conditions:
Gout Flare
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The aim of this study is to evaluate the efficacy and safety of simiaowan in prevention of acute flares in chronic gout patients initiating febuxostat therapy.
Detailed Description
The study is a multicenter, randomized, double-blind, placebo-controlled, 12-week trial. To determine whether oral simiaowan at standard clinical doses (6g twice daily), compared to placebo, can reduc...
Eligibility Criteria
Inclusion
- Male or female subjects aged 18 to 75 years (time of get informed consent)
- Meet the American College of Rheumatology/The European League Against Rheumatism criteria (2015) for the classification of acute arthritis of primary gout
- Pain Visual Analogue Scale Score (VAS) ≤ 3 at screening
- Serum uric acid ≥7 mg/dL (420μmol/L) at screening
- Self-reported history of at least 2 gout flares within 12 months prior to screening
- Normal electrocardiogram (ECG), or no clinical significant at screening
- Be capable of understanding and complying with protocol requirements
Exclusion
- Occurrence of an acute gout flare ongoing at screening or within 2 weeks prior to screening
- Known or suspected of secondary hyperuricemia (e.g. due to renal disorder, hematological disorder, drugs, radiotherapy, chemotherapy or organ transplant)
- Use of colchicine, allopurinol, probenecid, benzbromarone, febuxostat or history of intra-articular steroid injection within 4 weeks prior to screening
- Use of glucocorticoids, nonsteroidal antiinflammatory drugs (NSAIDs), or cyclooxygenase-2 (COX-2) inhibitors within 1 week prior to screening
- History of stroke, transient ischemic attack (TIA), acute myocardial infarction (MI), heart failure (NYHA Class II-IV), coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization) prior to screening
- History of gastrointestinal (GI) bleeding, peptic ulcer disease prior to screening
- History of malignancy and/or mental disorder prior to screening
- Active infection with hepatitis B, hepatitis C, or has aspartate transaminase (AST), alanine aminotransferase (ALT) or gamma-glutamyl transpeptidase (GGT) values ≥1.2 times the upper limit of normal (×ULN) during the screening period
- Presence of severe renal function impairment, or has serum creatinine (sCr) values ≥1.2 (×ULN) during the screening period
- History of allergy or intolerance to febuxostat, diclofenac sodium, simiaowan and/or the placebo
- History of aspirin-induced asthma, or any other form of allergy to aspirin and other NSAIDs
- Other (non-gout) chronic arthritis, acute inflammatory arthritis, autoimmune diseases with arthritis at screening
- Being treated with simiaowan at screening
- Being treated with azathioprine, mercaptopurine, theophylline, cytotoxic agents at screening
- Diagnosis of drug or alcohol dependence or abuse or any condition requiring chronic daily use of pain medication
- Pregnant or nursing, or planning to become pregnant or father a child within 3 months after receiving the last dose of study drug
- Subjects who participated in another clinical study or clinical trial within 3 months prior to screening
- Any other condition(s) that will compromise the safety of the patient, prevent compliance with the study protocol, or compromise the quality of the clinical study, as judged by the investigator
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 28 2020
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT04069325
Start Date
September 1 2019
End Date
July 28 2020
Last Update
August 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guang'anmen Hospital
Beijing, Beijing Municipality, China, 100053